4-Formyl­phenyl 2,3,4,6-tetra-O-acetyl-β-d-glucopyran­oside

The pyran­oside ring in the title compound, C21H24O11, has a chair conformation with the substituted benzene ring occupying an equatorial position. The crystal packing is dominated by C—H⋯O inter­actions that lead to the formation of supra­molecular layers in the ab plane

trans-Di-chlorido-bis-(dimethyl sulfoxide-κO)bis-(4-fluoro-benzyl-κC(1))tin(IV):crystal structure and Hirshfeld surface analysis

The Sn(IV) atom in the title diorganotin compound, [Sn(C7H6F)2Cl2(C2H6OS)2], is located on a centre of inversion, resulting in the C2Cl2O2 donor set having an all-trans disposition of like atoms. The coordination geometry approximates an octa-hedron. The crystal features C-H⋯F, C-H⋯Cl and C-H⋯π inter-actions, giving rise to a three-dimensional network. The respective influences of the Cl⋯H/H⋯Cl and F⋯H/H⋯F contacts to the mol-ecular packing are clearly evident from the analysis of the Hirshfeld surface

4-Formyl­phenyl 2,3,4,6-tetra-O-acetyl-β-d-galactopyran­oside

The galactose ring in the title compound, C21H24O11, has a chair conformation with the substituted benzene ring occupying an equatorial position. The crystal packing features C—H⋯O inter­actions that lead to the formation of supra­molecular layers in the ab plane

trans-Di-chlorido-bis-(dimethyl sulfoxide-κO)bis-(4-fluoro-benzyl-κC(1))tin(IV):crystal structure and Hirshfeld surface analysis

The Sn(IV) atom in the title diorganotin compound, [Sn(C7H6F)2Cl2(C2H6OS)2], is located on a centre of inversion, resulting in the C2Cl2O2 donor set having an all-trans disposition of like atoms. The coordination geometry approximates an octa-hedron. The crystal features C-H⋯F, C-H⋯Cl and C-H⋯π inter-actions, giving rise to a three-dimensional network. The respective influences of the Cl⋯H/H⋯Cl and F⋯H/H⋯F contacts to the mol-ecular packing are clearly evident from the analysis of the Hirshfeld surface

Drug carriers in cancer therapy: Administration, formulation and characterization

ABSTRACT Besides the active ingredient, matters of administration are of tremendous importance for the performance of a drug. A variety of carriers, differing in morphology and composition can be applied to enhance the efficiency of pharmaceutical active compounds. This review addresses common administration routes for cancer chemotherapy, i.e. intravenous injection, oral and transdermal application, and presents related carriers. Emphasis has been placed on vesicular systems, which are particularly useful for intravenous and oral administration. In view of considerable morphological impacts on the performance of a drug, methods for the physico-chemical characterization of carriers, covering size, encapsulation efficiency and drug release, are addressed as well

Renewable resources-based approach to biantennary glycolipids

A new synthesis approach towards biantennary lipids of Guerbet glycoside type was developed based on oleic acid as sustainable resource. Functionalization of the double bond provided access to primary alcohols with α-branched C19-skeleton. Formulation studies with corresponding lactosides indicated formation of vesicles with high assembly stability. A relatively narrow bimodal size distribution of the latter, which turns into a narrow unimodal distribution of small vesicles upon addition of an ionic cosurfactant, suggests potential for a vesicular drug delivery system

Biomimetic Targeted Theranostic Nanoparticles for Breast Cancer Treatment

The development of biomimetic drug delivery systems for biomedical applications has attracted significant research attention. As the use of cell membrane as a surface coating has shown to be a promising platform for several disease treatments. Cell-membrane-coated nanoparticles exhibit enhanced immunocompatibility and prolonged circulation time. Herein, human red blood cell (RBC) membrane-cloaked nanoparticles with enhanced targeting functionality were designed as a targeted nanotheranostic against cancer. Naturally, derived human RBC membrane modified with targeting ligands coated onto polymeric nanoparticle cores containing both chemotherapy and imaging agent. Using epithelial cell adhesion molecule (EpCAM)-positive MCF-7 breast cancer cells as a disease model, the nature-inspired targeted theranostic human red blood cell membrane-coated polymeric nanoparticles (TT-RBC-NPs) platform was capable of not only specifically binding to targeted cancer cells, effectively delivering doxorubicin (DOX), but also visualizing the targeted cancer cells. The TT-RBC-NPs achieved an extended-release profile, with the majority of the drug release occurring within 5 days. The TT-RBC-NPs enabled enhanced cytotoxic efficacy against EpCAM positive MCF-7 breast cancer over the non-targeted NPs. Additionally, fluorescence images of the targeted cancer cells incubated with the TT-RBC-NPs visually indicated the increased cellular uptake of TT-RBC-NPs inside the breast cancer cells. Taken together, this TT-RBC-NP platform sets the foundation for the next-generation stealth theranostic platforms for systemic cargo delivery for treatment and diagnostic of cancer